Liver Biochemical Course, Serum HBV DNA and Liver Stiffness Measurement for Therapeutic Decisions in HBeAg-Negative Chronic Hepatitis B Infection

Charatcharoenwitthaya, Phunchai; Phisalprapa, Pochamana; Rungkaew, Pimpattana; Kajornvuthidej, Sorrayut; Bandidniyamanon, Wimolrak; Chainuvati, Siwaporn; Pausawasdi, Nonthalee; Nimanong, Supot; Chotiyaputta, Watcharasak; Leelakusolvong, Somchai; Atisook, Kanit; Tanwandee, Tawesak

doi:10.1016/s0016-5085(11)63720-7

Cited by 2 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five were prospective, three were retrospective and one was cross-sectional in study design. Study origins included two from North America (USA), 41,42 one from East Asia (Korea), 43 one from Southeast Asia (Thailand), 44 two from South Asia (India, Bangladesh), 45,46 two from Europe (France, Spain) 47,48 and one from the Middle East (Iran). 49 The majority of studies occurred in a university or tertiary referral setting.…”

Section: Study and Patient Characteristicsmentioning

confidence: 99%

“…49 The majority of studies occurred in a university or tertiary referral setting. Six studies [41][42][43][45][46][47] involved both HBeAg-positive and HBeAg-negative patients, whereas the remaining three studies 44,48,49 evaluated only HBeAg-negative patients. All studies had a majority of male patients with the mean age ranging from 26.8 to 47.5 years old.…”

Section: Study and Patient Characteristicsmentioning

confidence: 99%

“…[41][42][43][44] Significant fibrosis (stage ≥2) was detected in 17.4% (95% CI: 14.4-27.7%). No significant heterogeneity was observed in this group (Q-statistic = 3.79, P = 0.29; I 2 = 20.8%).…”

Section: 45mentioning

confidence: 99%

“…41,[43][44][45][46] Among the five studies evaluating Asian CHB patients with ALT ≤40 IU/L, significant fibrosis (stage ≥2) was detected in 20.5% (95% CI: 15.2-27.0%). Significant heterogeneity was detected (Q-statistic = 10.4, P = 0.03; I 2 = 61.6%).…”

Section: Asian Patientsmentioning

confidence: 99%

See 3 more Smart Citations

Systematic review with meta‐analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤40 IU/L and significant hepatic fibrosis

Chao

Lim

Ayoub

et al. 2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Study and Patient Characteristicsmentioning

confidence: 99%

Section: Study and Patient Characteristicsmentioning

confidence: 99%

Section: 45mentioning

confidence: 99%

Section: Asian Patientsmentioning

confidence: 99%

See 2 more Smart Citations

Systematic review with meta‐analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤40 IU/L and significant hepatic fibrosis

Chao

Lim

Ayoub

et al. 2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…We have identified 20.000 IU/mL as the cut off value for HBV DNA because HBV DNA is used in many researches (14,15,16,17,18,19,20) and guidelines (7,12,13) to standardize rather than receiver operating characteristics (ROC). For the same reason, the cut off value for ALT was determined as 19 U/L for women and 30 U/L for men (13,14,20,21). We allocated two patient groups with regard to ALT levels: low-normal ALT (LNALT) (for women <19 U/L, for men <30 U/L) and high-normal ALT (HNALT) (for women 19-35, U/L for men 30-45 U/L).…”

Section: Serological Biochemical and Hepatitis B Virus Dna Assaymentioning

confidence: 99%

A Misleading Parameter in the Diagnosis of Chronic Hepatitis B: Persistently Normal Transaminases

Özdoğan¹,

Yaraş²,

Köksal³

et al. 2018

vhd

View full text Add to dashboard Cite

Objectives: Most of the patients with hepatitis B e (HBe)-negative hepatitis B have persistently normal transaminases (PNALT) levels. Patients, who have higher fibrosis and necroinflammatory activity scores, are at high risk for hepatocellular carcinoma and cirrhosis. Therefore, it is important to distinguish between active and inactive hepatitis in this group. Materials and Methods: Sixty-six treatment-naïve, non-cirrotic, HBe antigen (HBeAg)-negative and a PNALT and a level of a hepatitis B virus (HBV) DNA level of ≥2000 IU/mL were included in this study. Ishak's scoring system was used for histopathological evaluation. Chronic hepatitis was defined as a fibrosis score of higher than/ equal to 2 and/or a histological activity index score of higher than 4. Results: The percentage of patients diagnosed with advanced fibrosis score and high necroinflammatory activity was 65% and 48%, respectively. Accordingly, 76% of patients were considered to have chronic hepatitis. Level of the HBV DNA was the most significant value for predicting chronic hepatitis. 94.1% of patients with a HBV DNA value over 20000 IU/mL had chronic hepatitis (p<0.001). Conclusion: As a result of this study, it has been found that the prevalence of chronic hepatitis in our country was high in HBeAgnegative patients with PNALT and a HBV DNA level higher than 2000 IU/mL. We recommend starting treatment in patients with a HBV DNA level higher than 20000 IU/mL without considering any other criteria. Close monitoring or biopsy is recommended in patients with HBV DNA values between 2000 and 20000 IU/mL.

show abstract

Liver Biochemical Course, Serum HBV DNA and Liver Stiffness Measurement for Therapeutic Decisions in HBeAg-Negative Chronic Hepatitis B Infection

Cited by 2 publications

References 0 publications

Systematic review with meta‐analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤40 IU/L and significant hepatic fibrosis

Systematic review with meta‐analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤40 IU/L and significant hepatic fibrosis

A Misleading Parameter in the Diagnosis of Chronic Hepatitis B: Persistently Normal Transaminases

Contact Info

Product

Resources

About